Get 40% Off
🔥 This hedge fund gained 26.16% in the last month. Get their top stocks with our free stock ideas tool.See stock ideas

BARDA extends support of development of Cerus' INTERCEPT RBCs

Published 05/09/2017, 11:07 AM
© Reuters.  BARDA extends support of development of Cerus' INTERCEPT RBCs
  • The U.S. Department of Health and Human Services' Biomedical Advanced Research and Development Authority (BARDA) exercises additional options under its contract with Cerus (CERS +2.3%) for the development of INTERCEPT red blood cells (RBCs). The new options are valued at $46.6M while the total value of the five-year contract will be valued as high as $186M.
  • The funds will support a Phase 3 study to assess the RBCs for the treatment of anemia in cardiovascular surgery patients and a UK-based study in patients undergoing exchange transfusion for sickle cell disease.
  • Another Phase 3, called RedeS, is comparing INTERCEPT RBCs to conventional RBCs in areas at risk for the Zika virus.
  • Now read: Aralez Pharmaceuticals Inc. 2017 Q1 - Results - Earnings Call Slides


Original article

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.